Evolus’ injectable neurotoxin, Jeuveau, which was approved in 2019 and rivals AbbVie's major blockbuster Botox, knows exactly what it is. It’s an aesthetic product and that’s all it wants to be: no ...

Crows' feet, frown lines, and forehead creases are all signs of a life full of facial expressions. And while some may be reminders of happy memories, it's also totally fine to want to smooth them away ...

FDA issued 18 warning letters to websites selling unapproved or misbranded botulinum toxin products. Officials say the ...

When it comes to a scraped knee, you probably reach for a Band-Aid. Sneeze attack? Kleenex, please! Sometimes a brand is so good, so ubiquitous, that it defines an industry. The same could be said for ...

Please provide your email address to receive an email when new articles are posted on . New phase 2 results showed 40 units of Jeuveau sustained improvements in glabellar lines up to 6 months. Adverse ...

Evolus is shaking up promotion of its Botox rival. The old campaign was supporting above-market growth of wrinkle-busting product Jeuveau, but Evolus wants more, leading it to launch new branding ...

Plastic surgeons reveal the real timeline—and the surprising factors that either make it wear off faster or stick around longer.

Ten years from now, eliminating frown lines and other wrinkles with injectable neurotoxins will be as commonplace as any other beauty treatment at the salon, according to executives at Newport ...

This small-cap stock is going after a billion-dollar market. Jeuveau is an injectable serum containing the botulinum toxin type A compound, the same active ingredient that's in Botox and other facial ...

Evolus, Inc., a pharmaceutical company specializing in aesthetic products, faces significant challenges with its lead product Jeuveau, a treatment for frown lines. Jeuveau's undifferentiated clinical ...

Here’s what you need to know about the “mystery liquids” being sold to cost-cutters and unqualified injectors.